Morepen Laboratories per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹3.43₹1.73₹2.20₹1.88₹0.77
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹3.43₹1.73₹2.20₹1.88₹0.77
₹22.75₹22.75₹21.10₹16.58₹14.73
₹41.71₹32.96₹33.06₹33.07₹27.73
—₹0.60₹0.59₹1.44−₹1.78
−₹2.33−₹2.33−₹3.32−₹0.16−₹2.68
—₹0.20₹0.00₹0.00₹0.00
54.854.854.851.151.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health
₹ CrorePeersIOLCPINNOVACAPFDCORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,881 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS0.771.882.201.733.43
Diluted EPS0.771.882.201.733.43
Book Value per Share14.7316.5821.1022.7522.75
Revenue per Share27.7333.0733.0632.9641.71
Cash Flow per Share-1.781.440.590.60—
Free Cash Flow per Share-2.68-0.16-3.32-2.33-2.33
Dividends per Share0.000.000.000.20—
Shares Outstanding (cr)51.151.154.854.854.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.